GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 233 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $32,743,000 | +136.6% | 480,794 | +11.0% | 0.01% | +140.0% |
| Q2 2022 | $13,839,000 | -8.3% | 433,143 | -0.5% | 0.01% | 0.0% |
| Q1 2022 | $15,086,000 | +22.2% | 435,500 | +3.3% | 0.01% | +25.0% |
| Q4 2021 | $12,344,000 | +20.6% | 421,707 | +5.0% | 0.00% | +33.3% |
| Q3 2021 | $10,235,000 | -31.1% | 401,677 | -5.3% | 0.00% | -40.0% |
| Q2 2021 | $14,851,000 | +22.7% | 424,055 | +42.8% | 0.01% | +25.0% |
| Q1 2021 | $12,101,000 | -11.4% | 296,951 | -5.8% | 0.00% | -20.0% |
| Q4 2020 | $13,659,000 | -20.3% | 315,363 | +1.5% | 0.01% | -37.5% |
| Q3 2020 | $17,130,000 | -12.4% | 310,646 | +0.3% | 0.01% | -20.0% |
| Q2 2020 | $19,551,000 | -5.0% | 309,689 | -23.1% | 0.01% | -16.7% |
| Q1 2020 | $20,585,000 | -31.0% | 402,908 | +7.4% | 0.01% | -25.0% |
| Q4 2019 | $29,817,000 | +67.6% | 375,095 | +2.3% | 0.02% | +60.0% |
| Q3 2019 | $17,788,000 | +3.9% | 366,593 | +12.7% | 0.01% | 0.0% |
| Q2 2019 | $17,115,000 | +2.9% | 325,365 | +3.5% | 0.01% | -9.1% |
| Q1 2019 | $16,632,000 | +37.5% | 314,217 | +6.6% | 0.01% | +22.2% |
| Q4 2018 | $12,099,000 | +13.4% | 294,724 | +4.9% | 0.01% | +28.6% |
| Q3 2018 | $10,673,000 | -8.5% | 280,856 | +8.8% | 0.01% | -22.2% |
| Q2 2018 | $11,669,000 | +13.4% | 258,143 | +21.1% | 0.01% | +12.5% |
| Q1 2018 | $10,293,000 | +48.2% | 213,105 | +20.8% | 0.01% | +33.3% |
| Q4 2017 | $6,944,000 | +45.1% | 176,444 | +14.5% | 0.01% | +50.0% |
| Q3 2017 | $4,786,000 | +16.9% | 154,119 | +3.0% | 0.00% | 0.0% |
| Q2 2017 | $4,093,000 | +0.2% | 149,634 | +35.0% | 0.00% | 0.0% |
| Q1 2017 | $4,084,000 | +325.4% | 110,805 | +66.8% | 0.00% | +300.0% |
| Q4 2016 | $960,000 | -33.6% | 66,422 | +5.9% | 0.00% | -50.0% |
| Q3 2016 | $1,446,000 | +169.8% | 62,726 | +94.3% | 0.00% | +100.0% |
| Q2 2016 | $536,000 | +70.7% | 32,290 | +63.5% | 0.00% | – |
| Q1 2016 | $314,000 | -49.8% | 19,754 | +2.1% | 0.00% | -100.0% |
| Q4 2015 | $626,000 | +145.5% | 19,346 | +220.3% | 0.00% | – |
| Q3 2015 | $255,000 | – | 6,040 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 595,473 | $25,790,000 | 4.19% |
| Grace Capital | 131,549 | $5,697,000 | 3.60% |
| Fernwood Investment Management, LLC | 201,657 | $8,734,000 | 3.44% |
| Fairmount Funds Management LLC | 215,000 | $9,312,000 | 3.33% |
| Arctis Global LLC | 293,700 | $12,720,000 | 2.74% |
| Perceptive Advisors | 5,674,711 | $245,771,000 | 2.64% |
| ArchPoint Investors | 217,510 | $9,420,000 | 2.61% |
| Alerce Investment Management, L.P. | 126,270 | $5,469,000 | 2.15% |
| Profit Investment Management, LLC | 42,196 | $1,826,000 | 1.17% |
| Affinity Asset Advisors, LLC | 50,000 | $2,166,000 | 1.15% |